The International League Against Epilepsy (ILAE) Task Force on Nosology and Definitions proposes a classification and definition of epilepsy syndromes in the neonate and infant with seizure onset up to 2 years of age.
SUDEP
We demonstrated that the population using the SeizureTracker™ tool can be a valuable population for expanding investigation of SUDEP risk factors and is a first step towards establishing a large sample with a method to ascertain data prospectively that might be critical to developing a SUDEP risk algorithm.
Among patients with Lennox-Gastaut syndrome (LGS), the percentage reduction in the frequency of drop seizures is greater with fenfluramine versus placebo, according to a study published online May 2 in JAMA Neurology.
Featuring the research of former CURE Epilepsy grantee Dr. Juliet Knowles.
Calculus. Ballroom dancing. The words to your favorite song. There’s practically no limit to what your brain can learn. But a new study suggests that the same process that allows you to hold onto new information and skills could also make certain neurological diseases worse.
Children with Dravet syndrome, a severe form of epilepsy that begins in infancy, experience seizures, usually for their entire life. They are at high risk of sudden unexpected death in epilepsy (SUDEP) and can also develop intellectual disability and autism. Available treatments typically fail to improve these symptoms.
“The studies included in this review have shown that many ASMs were excreted into breastmilk in high concentrations,” the researchers said. “However, the majority of these ASMs did not produce significant adverse effects that warrant discontinuation of breastfeeding.”
anti-seizure medication withdrawal at ?16?years of age and a diagnosis other than juvenile absence epilepsy may be independent risk factors for seizure recurrence after drug withdrawal in adolescent patients.
We demonstrate that assessment of TBI-induced hippocampal deformation by clinically translatable MRI methodologies detects subjects with prior TBI as well as those at high-risk of PTE, paving the way towards subject stratification for antiepileptogenesis studies.
The present study by CURE Epilepsy grantee Dr. Scott Baraban extends this approach to a preclinical zebrafish model representing STXBP1-related disorders, and suggests that future clinical studies may be warranted.
